MENU
BDTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Black Diamond Therapeutics (BDTX) Ownership - Who owns Black Diamond Therapeutics?

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer... Show more

Profile

Industry
N/A
Address
One Main Street
Phone
+1 617 252-0848
Employees
54
Web
https://www.blackdiamondtherapeutics.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
87.54M
P/E Ratio
N/A
Total Cash
98.58M
Projected Growth
N/A
Total Debt
22.19M
Revenue
N/A
Risk (Beta)
3.58
Dividend Yield
N/A
Total Cash/Share
1.74
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

BDTX
Capitalization
87.5M
P/E Ratio
N/A
Risk (Beta)
3.58
Dividend Yield
N/A
Total Cash
98.6M
Total Cash/Share
1.74
Total Debt
22.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
83.3M
P/B Ratio
1.01
Cash Flow
N/A
Earnings
-1.27
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
4.92
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-78.44M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-49.55
Shares Held By Institutions
199M
Shares Outstanding - Current
56.7M
Total Liabilities
39.4M
Total Volume MTD
N/A
Value
1
Gain YTD
-30.374
View a ticker or compare two or three
BDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
One Main Street
Phone
+1 617 252-0848
Employees
54
Web
https://www.blackdiamondtherapeutics.com